|
ABT-751 in Treating Children With Refractory Solid Tumors Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about ABT-751 in Treating Children With Refractory Solid Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. ABT-751 in Treating Children With Refractory Solid Tumors Clinical research trials and ABT-751 in Treating Children With Refractory Solid Tumors medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as ABT-751 in Treating Children With Refractory Solid Tumors. ABT-751 in Treating Children With Refractory Solid Tumors Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a ABT-751 in Treating Children With Refractory Solid Tumors clinical trial. Participants frequently get the best healthcare available for their ABT-751 in Treating Children With Refractory Solid Tumors condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > ABT-751 in Treating Children With Refractory Solid Tumors  ABT-751 in Treating Children With Refractory Solid Tumors
ABT-751 in Treating Children With Refractory Solid Tumors
For Condition: childhood cancer
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ABT-751 in treating children who have refractorysolid tumors.
Details: OBJECTIVES: Primary - Determine the maximum tolerated dose and dose-limiting toxic effects of ABT-751 administered daily for 7 days every 21 days or daily for 21 days every 28 days in children with refractory solid tumors. - Determine the toxicity spectrum of these regimens in these patients. - Determine the pharmacokinetics of these regimens in these patients. - Evaluate the pharmacodynamics of this drug by measuring the fraction of tubulin that is polymerized in the peripheral blood mononuclear cells of these patients before and after receiving this drug. Secondary - Quantify responses in patients treated with these regimens. - Assess the effect of this drug on tumor vascularity and tumor blood flow using dynamic enhanced MRI in these patients. OUTLINE: This is an open-label, multicenter, dose-escalation study of 2 different schedules of ABT-751. Patients are assigned to 1 of 2 dosing schedules. - Schedule 1: Patients receive oral ABT-751 once daily on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. - Schedule 2: Patients receive oral ABT-751 once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. On each schedule, cohorts of 3-6 patients receive escalating doses of ABT-751 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 9 patients (a minimum of 3 patients age 11 and under and 3 patients age 12 to 18) are treated at the MTD. PROJECTED ACCRUAL: A maximum of 48 patients (24 per dosing schedule) will be accrued for this study within 2-4 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /18 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor, including, but not limited to, the following: - Rhabdomyosarcoma - Other soft tissue sarcomas - Ewing's sarcoma family of tumors - Osteosarcoma - Neuroblastoma - Wilms' tumor - Hepatic tumors - Germ cell tumors - Primary brain tumors - Brain stem or optic gliomas (histological confirmation may be waived if a biopsy has not been performed) - Relapsed after or failed to respond to frontline standard therapy and no other standard treatment options (e.g., surgery, radiotherapy, chemotherapy, or any combination of these modalities) exist - Measurable or evaluable disease - No CNS tumor with motor or sensory deficits that would obscure the study assessment of sensory neuropathy PATIENT CHARACTERISTICS: Age: - 18 and under Performance status: - Lansky 60-100% (age 10 and under) - Karnofsky 60-100% (age 11 to 18) Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - ALT and AST no greater than 2.5 times ULN - No clinically significant hepatic dysfunction Renal: - Creatinine normal for age OR - Creatinine clearance at least 60 mL/min - No clinically significant renal dysfunction Cardiovascular: - LVEF normal by echocardiogram Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No allergy to sulfa-containing medications - No clinically significant unrelated systemic illness (e.g., other organ dysfunction) that would preclude study participation - No serious infection - No preexisting grade 2 or greater sensory or motor neuropathy - Able to swallow intact capsules - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 months since prior bone marrow transplantation - At least 72 hours since prior interleukin-11 - At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa - No concurrent growth factors (e.g., GM-CSF) except epoetin alfa - No concurrent immunotherapy - No concurrent interleukin-11 Chemotherapy: - See Disease Characteristics - At least 30 days since prior chemotherapy (42 days for nitrosoureas) - No other concurrent anticancer chemotherapy Endocrine therapy: - Patients with brain tumors: - Must be on a stable or tapering dose of corticosteroids for 7 days before baseline scan performed for the purpose of assessing response to study therapy - Concurrent corticosteroids allowed for control of symptoms of tumor-associated edema Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy - At least 4 months since prior extensive radiotherapy (craniospinal radiotherapy, total body irradiation, or radiotherapy to more than 50% of the pelvis) - No concurrent radiotherapy Surgery: - See Disease Characteristics Other: - Recovered from prior therapy - At least 30 days since prior investigational anticancer therapy - No other concurrent investigational agents
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SteveCho, Study Chair, Pediatric Oncology Branch
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support *Recruiting*
Bethesda, Maryland, 20892-1182
United States
Recruiting Patient Recruitment 888-NCI-1937
Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19104-4318
United States
Recruiting Peter Adamson 215-590-5448
Children's Memorial Hospital - Chicago *Recruiting*
Chicago, Illinois, 60614
United States
Recruiting Susan Cohn 773-880-4562
Additional Information:
Study ID Numbers: CDR0000069344; NCI-02-C-0141D,ABBOTT-M01-357
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036959
Other Childhood Cancer Studies:
1. ABT-751 in Treating Children With Refractory Solid Tumors
2. Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
3. Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Related Studies:
Other childhood cancer Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
ABT-751 in Treating Children With Refractory Solid Tumors
|
|
|
|
|
|
|
|
